Related Experiment Video
Updated: Jun 20, 2026

Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
ErbB2 resembles an autoinhibited invertebrate epidermal growth factor receptor
Diego Alvarado1, Daryl E Klein, Mark A Lemmon
1Department of Biochemistry and Biophysics, University of Pennsylvania School of Medicine, 809C Stellar-Chance Laboratories, 422 Curie Boulevard, Philadelphia, Pennsylvania 19104-6059, USA.
Abstract:
The orphan receptor tyrosine kinase ErbB2 (also known as HER2 or Neu) transforms cells when overexpressed, and it is an important therapeutic target in human cancer. Structural studies have suggested that the oncogenic (and ligand-independent) signalling properties of ErbB2 result from the absence of a key intramolecular 'tether' in the extracellular region that autoinhibits other human ErbB receptors, including the epidermal growth factor (EGF) receptor. Although ErbB2 is unique among the four human ErbB receptors, here we show that it is the closest structural relative of the single EGF receptor family member in Drosophila melanogaster (dEGFR). Genetic and biochemical data show that dEGFR is tightly regulated by growth factor ligands, yet a crystal structure shows that it, too, lacks the intramolecular tether seen in human EGFR, ErbB3 and ErbB4. Instead, a distinct set of autoinhibitory interdomain interactions hold unliganded dEGFR in an inactive state. All of these interactions are maintained (and even extended) in ErbB2, arguing against the suggestion that ErbB2 lacks autoinhibition. We therefore suggest that normal and pathogenic ErbB2 signalling may be regulated by ligands in the same way as dEGFR. Our findings have important implications for ErbB2 regulation in human cancer, and for developing therapeutic approaches that target novel aspects of this orphan receptor.
Insights
The orphan receptor tyrosine kinase ErbB2 (HER2) may be regulated by ligands, similar to Drosophila melanogaster EGFR (dEGFR). This finding challenges the notion that ErbB2 lacks autoinhibition and offers new therapeutic targets for cancer.
Area of Science:
- Molecular biology
- Structural biology
- Cancer research
Background:
- ErbB2 (HER2) is an oncogenic receptor tyrosine kinase and a key therapeutic target in cancer.
- Previous models suggested ErbB2's oncogenic signaling stems from lacking an autoinhibitory tether present in other ErbB receptors.
- The structural basis for ErbB2's unique signaling and regulation remained unclear.
Purpose of the Study:
- To investigate the structural and regulatory mechanisms of ErbB2 signaling.
- To compare ErbB2 regulation with its closest structural relative, Drosophila melanogaster EGFR (dEGFR).
- To re-evaluate the autoinhibition model for ErbB2.
Main Methods:
- Comparative structural analysis of ErbB2 and dEGFR.
- Genetic and biochemical assays to study dEGFR regulation by ligands.
- Crystal structure determination of dEGFR.
Main Results:
- dEGFR, despite lacking the canonical tether, is tightly regulated by growth factor ligands.
- A distinct set of interdomain interactions maintains unliganded dEGFR in an inactive state.
- These autoinhibitory interactions are conserved and extended in ErbB2, contradicting the absence of autoinhibition.
Conclusions:
- ErbB2 autoinhibition is present and likely regulated by ligands, similar to dEGFR.
- The established model of ErbB2 lacking autoinhibition is challenged.
- Findings provide novel insights into ErbB2 regulation and potential therapeutic strategies for ErbB2-driven cancers.
Related Concept Videos
Mitogens and the Cell Cycle
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
Role of Ephrin-Eph Signalling in Intestinal Stem Cell Renewal
Cell Signaling in Plants
Receptor Tyrosine Kinases
The Ras Gene
Ras is a superfamily...

